Modality
Cell Therapy
MOA
CD47i
Target
PRMT5
Pathway
Apoptosis
ThymomaGISTRCC
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
Oct 2021
→ Jan 2028
Phase 2Current
NCT07071228
2,769 pts·Thymoma
2021-12→2027-05·Terminated
NCT08734902
574 pts·GIST
2021-10→2028-01·Completed
3,343 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-05-161.1y awayPh3 Readout· Thymoma
2028-01-121.8y awayPh3 Readout· GIST
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Complet…
P2/3
Termina…
Catalysts
Ph3 Readout
2027-05-16 · 1.1y away
Thymoma
Ph3 Readout
2028-01-12 · 1.8y away
GIST
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07071228 | Phase 2/3 | Thymoma | Terminated | 2769 | ORR |
| NCT08734902 | Phase 2/3 | GIST | Completed | 574 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Zenonesiran | GSK | Preclinical | DLL3 |